Khalid Shoumariyeh
Overview
Explore the profile of Khalid Shoumariyeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rufer A, Nilius H, Hermine O, Niedoszytko M, Oude Elberink J, Bonadonna P, et al.
Leukemia
. 2025 Jan;
39(3):675-683.
PMID: 39815050
Expression of CD2, CD25 and/or CD30 in extracutaneous mast cells (MC) is a minor diagnostic criterion for systemic mastocytosis (SM) in the classification of the World Health Organization and International...
2.
Shoumariyeh K, Csernalabics B, Salimi Alizei E, Reinscheid M, Giese S, Ciminski K, et al.
Vaccines (Basel)
. 2024 Nov;
12(11).
PMID: 39591152
Background: Multiple myeloma (MM) patients are at high risk of severe infections including COVID-19 due to an immune dysregulation affecting both innate and adaptive immune responses. However, our understanding of...
3.
Schmidt D, Endres C, Hoefflin R, Andrieux G, Zwick M, Karantzelis N, et al.
Cancer Res
. 2024 Jun;
84(18):2985-3003.
PMID: 38885318
Increasing evidence supports the interplay between oncogenic mutations and immune escape mechanisms. Strategies to counteract the immune escape mediated by oncogenic signaling could provide improved therapeutic options for patients with...
4.
Niedoszytko M, Gorska A, Brockow K, Bonadonna P, Lange M, Kluin-Nelemans H, et al.
Allergy
. 2024 Apr;
79(9):2470-2481.
PMID: 38651829
Background: Hypersensitivity reactions (HR) are common in mastocytosis. However, little is known about triggers and risk factors. The registry of the European Competence Network on Mastocytosis (ECNM) enables reliable studies...
5.
Lubke J, Schmid A, Christen D, Oude Elberink H, Span L, Niedoszytko M, et al.
Blood Adv
. 2024 Apr;
8(11):2890-2900.
PMID: 38593217
Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607...
6.
Lubke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K, et al.
Leukemia
. 2024 Mar;
38(4):810-821.
PMID: 38448757
We identified 71 patients with AdvSM (aggressive SM [ASM], SM with an associated hematologic neoplasm [SM-AHN, e.g., acute myeloid leukemia, SM-AML], mast cell leukemia [MCL]) in two national registries (DRST/GREM)...
7.
Maas-Bauer K, Stell A, Yan K, de Vega E, Vinnakota J, Unger S, et al.
Nat Commun
. 2024 Jan;
15(1):446.
PMID: 38199985
Patients with corticosteroid-refractory acute graft-versus-host disease (aGVHD) have a low one-year survival rate. Identification and validation of novel targetable kinases in patients who experience corticosteroid-refractory-aGVHD may help improve outcomes. Kinase-specific...
8.
Zhang Y, Velasco-Hernandez T, Mess J, Lalioti M, Romero-Mulero M, Obier N, et al.
Blood Adv
. 2023 Aug;
7(24):7525-7538.
PMID: 37639313
Leukemia stem cells (LSCs) share numerous features with healthy hematopoietic stem cells (HSCs). G-protein coupled receptor family C group 5 member C (GPRC5C) is a regulator of HSC dormancy. However,...
9.
Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk A, et al.
Br J Haematol
. 2023 Aug;
203(2):264-281.
PMID: 37539479
Acute myeloid leukaemia (AML) relapse after allogeneic haematopoietic cell transplantation (allo-HCT) is often driven by immune-related mechanisms and associated with poor prognosis. Immune checkpoint inhibitors combined with hypomethylating agents (HMA)...
10.
Langhammer M, Schopf J, Jaquet T, Horn K, Angel M, Spohr C, et al.
Leukemia
. 2023 May;
37(7):1474-1484.
PMID: 37161070
The persistence of leukemic stem cells (LSCs) represents a problem in the therapy of chronic myeloid leukemia (CML). Hence, it is of utmost importance to explore the underlying mechanisms to...